viewPharmaxis Ltd

Pharmaxis features in APAC’s top 100 most innovative pharma companies report

Pharmaxis was ranked 38 out of the 100 companies named as innovators in the small to medium- sized enterprises category.

Pharmaxis Ltd - Pharmaxis features in APAC’s top 100 most innovative pharma companies report
Pharmaxis is one of 14 Australian companies included in the top 100 and is ranked second of the 14

Pharmaxis Ltd (ASX:PXS) has been included in a new report which ranks the company among the top 100 most innovative pharma companies in the Asia Pacific (APAC) region.

The report was prepared by Cortellis and is entitled “Pharmaceutical innovation in the APAC region”.

It studied a cohort of 929 companies including multi-nationals across 14 countries/regions that have or are developing innovative pharmaceutical products.

Fourteen Australian companies featured in the top-100 and Pharmaxis was the second-highest ranked of the14.

Translating R&D into results

Pharmaxis’ CEO Gary Phillips said: “I’m delighted but not surprised that Pharmaxis has been recognised in this report, the first of its kind.

“We have clearly met key indicators such as being able to demonstrate a strong pipeline and translate our R&D into actual drug candidates.

“Early stage partnering was also a measure studied for the report and Pharmaxis has made this a key business objective.”

Track record of delivering value

The company’s ability to create value for shareholders through R&D is best exemplified by its 2015 deal with Boehringer.

Pharmaxis sold its anti‐inflammatory drug candidate to Boehringer in a deal structured to deliver potential value in excess of $A750 million.

The Pharmaxis drug discovery team has moved four drugs into the clinic over the last five years.

The company’s pipeline is focused on anti‐fibrotic agents to treat a variety of diseases through inhibiting the LOX and LOXL2 enzymes.

The LOXL2 inhibition program is currently in a commercial partnering process.

Quick facts: Pharmaxis Ltd

Price: 0.105 AUD

Market: ASX
Market Cap: $41.5 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...



Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® . The move addresses issues raised by the US Food and Drug Administration (FDA)...

on 6/5/20

2 min read